Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.010
+0.152 (17.73%)
At close: Jan 6, 2026, 4:00 PM EST
1.080
+0.070 (6.93%)
After-hours: Jan 6, 2026, 7:25 PM EST
Skye Bioscience Employees
Skye Bioscience had 16 employees as of December 31, 2024. The number of employees increased by 5 or 45.45% compared to the previous year.
Employees
16
Change (1Y)
5
Growth (1Y)
45.45%
Revenue / Employee
n/a
Profits / Employee
-$3,201,833
Market Cap
32.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 5 | 45.45% |
| Dec 31, 2023 | 11 | 0 | - |
| Dec 31, 2022 | 11 | 2 | 22.22% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 2 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SKYE News
- 8 hours ago - INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - PRNewsWire
- 1 day ago - Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - PRNewsWire
- 4 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - GlobeNewsWire
- 8 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Newsfile Corp
- 15 days ago - SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Newsfile Corp
- 18 days ago - Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE. - Business Wire
- 4 weeks ago - Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation - PRNewsWire
- 6 weeks ago - Skye Bioscience to Participate in Upcoming Investment Conferences - Newsfile Corp